Cancer's genetic basis, encompassing somatic mutations and inherited predispositions, underpins the burgeoning field of personalized medicine.  Advances in genomics, particularly next-generation sequencing, have enabled the identification of driver mutations specific to individual tumors, facilitating targeted therapies. Bioinformatics plays a crucial role in analyzing vast genomic datasets, identifying patterns and predicting therapeutic response.  This necessitates collaboration between oncologists, geneticists, bioinformaticians, and pharmaceutical scientists.

Personalized medicine integrates these disciplines to tailor treatment strategies.  Identifying a patient's unique genetic profile allows for the selection of drugs that specifically target their cancer's driver mutations, maximizing efficacy and minimizing off-target effects.  Furthermore, pharmacogenomics explores the influence of an individual's genetic makeup on drug metabolism and response, contributing to optimized drug selection and dosage.  The integration of these interdisciplinary approaches offers a more precise and effective approach to cancer treatment, moving beyond one-size-fits-all approaches towards individualized therapies based on a patient's unique genetic landscape.